Stablix Therapeutics

Stablix Therapeutics is a biotechnology company at the forefront of the Targeted Protein Stabilization (TPS) field, pioneering a completely new area of targeted protein stabilization (TPS) to bring transformative drugs to patients with unmet medical needs. The company's RESTORED platform generates heterobifunctional small molecules (RESTORACS) that can recruit deubiquitinases to remove ubiquitin from target proteins, thereby stabilizing or increasing target protein levels and activity. Stablix is initially leveraging this platform to develop programs for treating rare diseases, cancer, and immune disorders. We are a creative and multidisciplinary team of scientists, innovators, and leaders dedicated to transforming the way we approach drug development by establishing robust small-molecule modalities for various debilitating diseases.